You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covid vaccination beneficiaries below target due to vaccine hesitancy: Govt

Fewer than planned beneficiaries attended the coronavirus vaccination sessions at the start due to transient technical issues in CoWIN portal and vaccine hesitancy, among others, the government said

Coronavirus | Coronavirus Vaccine

Press Trust of India  |  New Delhi 

Beneficiary gets a Covid-19 vaccine at City Dispensary, in Bikaner
Beneficiary gets a Covid-19 vaccine at City Dispensary, in Bikaner

Fewer than planned beneficiaries attended the vaccination sessions at the start due to transient technical issues in CoWIN portal and vaccine hesitancy, among others, the government informed the Parliament on Friday.

A total of 7,580 adverse events following immunisation have been reported till January 31 under the rollout. None of the 12 deaths of vaccinated persons have been causally attributed to the vaccination as per the current evidence, Minister of State for Health Ashwini Choubey told the Lok Sabha.

Responding to a question on the urgency on part of the government to go ahead with the vaccination when the cases are declining, Choubey said a second or third peak was experienced in other countries during the later part of the pandemic.

"Therefore, a declining trend of cases in the country does not necessarily promise a continued and steady decrease in cases," he said. "Hence, it is necessary to provide prompt protection to the vulnerable and at risk population and maintain low case count through COVID-19 vaccination."

As per the fact sheet of the vaccine manufactured by Bharat Biotech, one should not get Covaxin if the person has any allergies, fever, bleeding disorder or are on blood thinner, immune-compromised individuals or on medicines that affect immune system, pregnant, breastfeeding, received another vaccine or any serious health-related issues, Choubey said in a written reply.

As per the fact sheet of Serum Institute, one should not get Covishield if a person had a severe allergic reaction after a previous dose of this vaccine and had a severe allergic reaction to any ingredient of this vaccine, he said.

The healthcare provider needs to be consulted about medical conditions, including severe allergic reaction after any drug, food, any vaccine or any ingredients of Covishield; fever; bleeding disorder; immunocompromised; pregnant; breastfeeding or received another COVID-19 vaccine, the minister said.

Only those COVID-19 vaccines that have been granted permission for restricted use in emergency situation by the Drugs Controller General of India have been used for COVID-19 vaccination drive in the country.

As per New Drugs and Clinical Trials Rules, 2019, the Central Drugs Standard Control Organisation has granted permission to manufacture two vaccines based on the prescribed procedure and due evaluation of pre-clinical and clinical trial data.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, February 05 2021. 23:07 IST